NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

U.S. stock futures declined on Tuesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices fell, f

U.S. stocks fell Monday as tech slid; Nvidia may invest $10B in Anthropic’s IPO. Oil rose 3%, while

Nasdaq fell 1%, while Elmet surged 50.6% on $450M DoD funding plans; Rum, SailPoint, Tyra and cybers

Underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in

CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-s

Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell the securities identifi

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, I

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediat

Wedbush analyst Robert Driscoll reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and m

Analysts cut targets for AAPL, CHWY, COO, TYRA and CNM; raised DLR, DPZ, SIG, while ratings stayed u

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Tyra Biosciences (NASDAQ:TYRA) with

Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regula

Tyra Biosciences Inc. (NASDAQ:TYRA) stock is trading lower on Wednesday after the company shared ini

Tyra Biosciences stock fell sharply as initial dabogratinib Phase 2 data showed a 57% complete respo

Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder

Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early

Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre

CARLSBAD, Calif., Sept. 9, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-st

CARLSBAD, Calif., Sept. 8, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-st

Tyra Biosciences is downgraded to "Hold" ahead of key phase 2 SURF302 data for dabogratinib in FGFR3

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with

Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing n

CARLSBAD, Calif., Sept. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-st

Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) has received a consensus rating of "Moderate

Algert Global LLC increased its stake in shares of Tyra Biosciences, Inc. (NASDAQ: TYRA) by 27.2% in

5AM Venture Management LLC bought a new position in Tyra Biosciences, Inc. (NASDAQ: TYRA) in the und

TYRA's dabogratinib has an upcoming readout in September 2026 that I think could validate its FGFR3

Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.69) per share which missed the analy

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 d

Analysts change outlook on top Wall Street names. SNX, ORCL, EDU, ENS, SHOO, RH, have price target c

Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ra

Wall Street analysts change outlook on top names, including upgrades/downgrades. Check our analyst r

B of A Securities analyst Geoff Meacham maintains Tyra Biosciences (NASDAQ:TYRA) with a Buy and r

-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients li

Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates.

Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. Se

Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analyst

Wolfe Research analyst Kalpit Patel initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a P

Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary te

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with

Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.64) per share which missed the analy

'Top Wall Street analysts changed outlook on top names. See all rating changes incl. upgrades, d

Guggenheim analyst Brad Canino initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a Buy ra

Canaccord Genuity analyst John Newman initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a

Piper Sandler analyst Allison Bratzel maintains Tyra Biosciences (NASDAQ:TYRA) with a Overweight

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001863127/000119312526091880/d48655d8k.htm